9/17/2025- Chilvana Patel, MD moderates a discussion with Pushpa Narayanswami, MD, Nicholas Silvestri, MD, and Kelly Gwathmey, MD on the evolving treatment landscape in myasthenia gravis (MG). The panel reviews the use of targeted therapies in women of childbearing age with myasthenia gravis, alongside guidance for perioperative care before elective surgery. Through illustrative patient cases, the experts provide insight into practical challenges and emerging opportunities in tailoring advanced immunotherapies to individual patient needs. 26 min
7/31/2025- Chilvana Patel, MD is hosting a case-based panel discussion titled "Evolving Therapeutic Horizons in Myasthenia Gravis: Expert Perspectives on Targeted Therapies - Part 1." She will engage with renowned neuromuscular specialists—Pushpa Narayanaswami, MD, Nicholas Silvestri, MD, and Kelly Gwathmey, MD—to explore real-world cases and discuss the latest advances in targeted treatment options for Myasthenia Gravis. 31 min
12/15/2024- In this AANEM podcast, Carrie Ford, a CNCT and R.NCS.T. from the University of Utah's Jack Petajan EMG Lab, interviews Dr. Kyle Mahoney, an associate professor at the University of Utah, who provides a comprehensive explanation of neuromuscular junction transmission and the critical concept of the "safety factor." He breaks down complex neurophysiological concepts using accessible analogies, explaining how the safety factor serves as a built-in buffer that ensures reliable nerve-to-muscle signal transmission. The discussion covers normal neuromuscular junction function, the impact of various pathological conditions such as Lambert-Eaton Myasthenic Syndrome, myasthenia gravis, and ALS on neuromuscular transmission, and the clinical significance of repetitive nerve stimulation testing. Dr. Mahoney's clear explanations make these technically challenging concepts more approachable for healthcare professionals, particularly EMG technicians who may be less familiar with the underlying mechanisms of neuromuscular transmission. 24 min.
Join us in this episode as Devon Rubin, MD, challenges Professor Erik Stalberg with an unknown case and discusses various EMG approaches to a patient with suspected neuromuscular junction disease. Watch Professor Stalberg grade Dr. Rubin’s single fiber pairs and hearing about single fiber EMG on dogs will surely make you smile!
12/16/2021- Dr. Katarzyna Ibanez interviews Dr. Timothy Dillingham on evaluation of persons with suspected lumbosacral and cervical radiculopathy. 39 minutes
11/3/2021- Dr. Elahi Behzad interviews Dr. Michael H. Rivner on the clinical features of LRP4/agrin-antibody–positive Myasthenia Gravis. 21 minutes
7/24/2020- Dr. Justin Willer interviews Dr. Constantine Farmakidis on his article, Immunomodulatory and Immunosuppressive Therapy for Neuromuscular Disorders Part II. While traditional immunosuppressive and immunomodulatory therapies remain the cornerstone of immune-mediated neuromuscular disease management, new and novel agents including antigen-specific, monoclonal antibody drugs, have emerged as important treatment options. This article is the second of a two-part series that reviews immune-based therapies in neuromuscular diseases. The first article provides an update on the use of traditional immune-based therapies such as corticosteroids, plasma exchange, steroid-sparing immunosuppressive drugs, and intravenous immunoglobulin G. This second article focuses on new and novel immune-based therapies, including eculizumab, a complement inhibitor approved for acetylcholine receptor antibody-positive myasthenia gravis; rituximab, a B-cell depletion therapy with evolving indications in neuromuscular diseases; and the subcutaneous formulation of immunoglobulin G that gained approval for use in chronic inflammatory demyelinating polyradiculoneuropathy in 2018. Finally, several novel antigen-specific drugs at different stages of investigation in neuromuscular disease are also reviewed. 29 minutes
7/24/2020- Dr. Justin Willer interviews Dr. Constantine Farmakidis on his article, Immunomodulatory and Immunosuppressive Therapy for Neuromuscular Disorders Part I. While traditional immunosuppressive and immunomodulatory therapies remain the cornerstone of immune-mediated neuromuscular disease management, new and novel agents including antigen-specific, monoclonal antibody drugs, have emerged as important treatment options. This article is the second of a two-part series that reviews immune-based therapies in neuromuscular diseases. The first article provides an update on the use of traditional immune-based therapies such as corticosteroids, plasma exchange, steroid-sparing immunosuppressive drugs, and intravenous immunoglobulin G. This second article focuses on new and novel immune-based therapies, including eculizumab, a complement inhibitor approved for acetylcholine receptor antibody-positive myasthenia gravis; rituximab, a B-cell depletion therapy with evolving indications in neuromuscular diseases; and the subcutaneous formulation of immunoglobulin G that gained approval for use in chronic inflammatory demyelinating polyradiculoneuropathy in 2018. Finally, several novel antigen-specific drugs at different stages of investigation in neuromuscular disease are also reviewed. 1 hour 23 minutes